CURRENT RESEARCH - enrolling now

1. Surgical IIH Treatment Trial (SIGHT) for Idiopathic Intracranial Hypertention

 The National Eye Institue is sponsoring this NORDIC Investigator-initiated study to compare medical treatment and two types of surgical treatments for Idiopathic Intracranial Hypertension.

Find a list of doctors for the SIGHT studyenrolling now.  This trial is  being conducted by Neuro-Ophthalmologists in private practices and hospitals in the United States and Canada.

Read more from NORDIC on the background of this study.

 

2. Treatment Trial for Patients with previous, chronic Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Regenera Pharma and NORDIC are collaborating on a treatment trial to evaluate Regenera's novel drug, RPh201, an extract from a botanical source, to treat chronic Non-arteritic Anterior Ischemic Optic Neuropathy (NAION).

Find a list of doctors for the Regenera NAION study, enrolling now.  This trial is being conducted by Neuro-Ophthalmologists in private practices and hospitals in the United States.

Read more from NORDIC on the background of this study.

 

3. Treatment Trial for Patients with recent, acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Quark Pharmaceuticals and NORDIC are collaborating on an investigational drug trial to evaluate a neuroprotection therapy for acute Non-arteritic Anterior Ischemic Optic Neuropathy (NAION).  The trial is currently enrolling subjects who are 50-80 years old and have had sudden vision loss in one eye within the last 14 days.

Find a list of U.S. doctors for the Quark NAION study, enrolling now.  This trial is being conducted by Neuro-Ophthalmologists in private practices and hospitals in the United States, India, Israel, Italy, Germany, Australia, Singapore, and China.  Find a list of non-U.S. doctors.

Quark NAION Trial Patient FAQ's

Quark NAION Trial Doctor Fact Sheet  

Read more from the Sponsor, Quark's website

 

PAST RESEARCH - no longer enrolling

1. NORDIC has concluded a study on Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).  IIH, also called pseudotumor cerebri, is a disorder of elevated intracranial pressure of unknown case. Its incidence is 22.5 new cases each year per 100,000 overweight women of childbearing age; its incidence is rising in parallel with the obesity epidemic. It affects about 100,000 Americans.  Recruitment has concluded for this study. LEARN MORE

Publications 

NORDIC Idiopathic Intracranial Hypertension Study Group

OCT SUBSTUDY: NORDIC IIHTT STUDY GROUP

2. The Pediatric Optic Neuritis Prospective Outcomes Study was a now-concluded joint collaboration between NORDIC and the Pediatric Eye Disease Investigator Group (PEDIG).  This observational data collection study was funded by the National Eye Institute and aimed to determine investigators' ability to enroll children with optic neuritis into a research protocol, and help develop estimates of visual acuity outcomes in these children.